The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 290.00
Bid: 289.00
Ask: 293.00
Change: 0.00 (0.00%)
Spread: 4.00 (1.384%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 290.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NOTIFICATION OF MAJOR HOLDINGS

1 Nov 2017 09:45

RNS Number : 2399V
Hutchison China Meditech Limited
01 November 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Hutchison China MediTech Limited;

Legal Entity Identifier: 2138006X34YDQ6OBYE79

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Voluntary disclosure

X

3. Details of person subject to the notification obligationiv

Name

Hutchison Healthcare Holdings Limited

City and country of registered office (if applicable)

British Virgin Islands

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

30/10/2017

6. Date on which issuer notified (DD/MM/YYYY):

30/10/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

60.36%

60.36%

66,435,037

Position of previous notification (if

applicable)

60.36%

60.36%

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares (KYG4672N1016) and American Depositary Shares (US44842L1035)

40,097,877

60.36%

SUBTOTAL 8. A

40,097,877

60.36%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

CK Hutchison Holdings Limited - indirect, but ultimate, owner of the shareholder

60.36%

60.36%

Hutchison Whampoa (China) Limited - direct owner of the shareholder and a subsidiary of CK Hutchison Holdings Limited

60.36%

60.36%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

Voluntary notification following an offering of American Depository Shares by Hutchison China MediTech Limited.

 

Place of completion

Hong Kong

Date of completion

31 October 2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBBBLTMBJMMFR
Date   Source Headline
26th Mar 20187:00 amRNSAnnual Report & Notice of Annual General Meeting
21st Mar 20189:25 amRNSDirector's Share Dealing
20th Mar 20189:15 amRNSGrant of Share Options under Share Option Scheme
19th Mar 20187:10 amRNSDirector's Share Dealing
12th Mar 201811:22 amRNSPublication of Form 20-F
12th Mar 20187:02 amRNSFinal Results and Key Clinical Programs Update
6th Mar 20187:00 amRNSPhase Ib/II Trial of Epitinib in Glioblastoma
13th Feb 20187:01 amRNSEnrolment completed Ph III FALUCA Fruquintinib
5th Feb 20187:00 amRNSChi-Med to Announce 2017 Final Results
29th Dec 20177:00 amRNSBlock listing Interim Review
29th Dec 20177:00 amRNSTotal Voting Rights
15th Dec 20177:00 amRNSChi-Med Initiates Fruquintinib US Clinical Trials
1st Nov 20179:45 amRNSNotification of Major Holdings
1st Nov 20179:45 amRNSNOTIFICATION OF MAJOR HOLDINGS
31st Oct 20177:00 amRNSFRUTIGA, a Phase III trial of Fruquintinib
30th Oct 20173:30 pmRNSClosing of U.S. Public Offering of ADSs
27th Oct 201712:10 pmRNSChi-Med Announces Over-allotment Option
26th Oct 20177:00 amRNSChi-Med Announces Pricing Raising US$262 million
25th Oct 20177:00 amRNSChi-Med Announces Proposed Offering of ADSs
19th Oct 20179:20 amRNSNotification of Major Interest in Shares
17th Oct 20177:00 amRNSSavolitinib Shows Encouraging Clinical Activity
16th Oct 20177:00 amRNSChi-Med Reports Preliminary Phase II data
12th Oct 20177:30 amRNSAppointment of Director
29th Sep 20177:04 amRNSSavolitinib and Fruquintinib presentations at WCLC
29th Sep 20177:00 amRNSTotal Voting Rights
29th Sep 20177:00 amRNSOral Presentations at CSCO Annual Meeting
31st Aug 201710:15 amRNSDirector's Share Dealing
29th Aug 20177:00 amRNSStart of HMPL 689 Phase I Trial in China
22nd Aug 20179:00 amRNSDirector's Share Dealing
18th Aug 201710:50 amRNSDirectors' Share Dealing
15th Aug 201710:30 amRNSDirectors' Share Dealing
10th Aug 20179:35 amRNSDirector's Share Dealing
7th Aug 20179:45 amRNSDirectors' Share Dealing
31st Jul 20177:00 amRNSChi-Med Reports 2017 Interim Results
30th Jun 20177:00 amRNSTotal Voting Rights
29th Jun 20177:00 amRNSChi-Med to Announce 2017 HY Financial Results
29th Jun 20177:00 amRNSBlocklisting Six Monthly Return
29th Jun 20177:00 amRNSStart of Savolitinib Global PRCC Phase III Trial
22nd Jun 20177:00 amRNSChi-Med starts Ph I/II Trial of HMPL 453 in China
16th Jun 20179:57 amRNSDirector's Share Dealing
12th Jun 20177:00 amRNSFruquintinib NDA for Advanced CRC Filed with CFDA
6th Jun 20177:00 amRNSPhase III Fruquintinib Data presented at ASCO
18th May 20177:00 amRNSChi-Med Presents Clinical Data at ASCO 2017
28th Apr 20171:40 pmRNSTotal Voting Rights
27th Apr 20172:10 pmRNSResults of Annual General Meeting
7th Apr 20177:00 amRNSPre-clinical Data Presented at AACR
31st Mar 20177:00 amRNSTotal Voting Rights
29th Mar 20178:07 amRNSVesting of LTIP awards
28th Mar 201711:00 amRNSGrant of Share Options under Share Option Scheme
27th Mar 20177:00 amRNS2016 Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.